SNCA and Parkinson disease: Specifically, pS129 SNCA represents a particularly interesting SNCA modification as it is enriched in aggregated and misfolded SNCA in PD tissues (reviewed in Oueslati, 2016), it exacerbates pathology and induces neuronal dysfunction in mice (Karampetsou et al., 2017) and its plasma levels are increased in PD (Foulds et al., 2011, 2013).